Reyes Financial Architecture’s Calidi Biotherapeutics CLDI Stock Holding History

Reyes Financial Architecture’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-6	Closed	-$17	–	553
2026 Q2	$17	Hold	6	–	–	﹤0.01%	317
2026 Q1	$24	Hold	6	–	–	﹤0.01%	347
2025 Q4	$117	Hold	6	–	–	﹤0.01%	384
2025 Q3	$152	Buy	+6	New	+$408	﹤0.01%	299

Other funds holding CLDI

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Reyes Financial Architecture's CLDI Position: Q3 2026 in Review

Reyes Financial Architecture sold out of Calidi Biotherapeutics (CLDI) in Q3 2026, closing a stake of 6 shares — an estimated $17 sold.

Reyes Financial Architecture first reported a position in CLDI in Q3 2025 and held it in 4 quarters. The position peaked at $152 in Q3 2025. 2 funds tracked by Wall St. Rank hold CLDI as of Q3 2026.

Reyes Financial Architecture reported no remaining Calidi Biotherapeutics position as of Q3 2026 after selling out during the quarter.
Reyes Financial Architecture sold 6 Calidi Biotherapeutics shares in Q3 2026, an estimated $17.
Reyes Financial Architecture first reported a position in Calidi Biotherapeutics in Q3 2025 and held it in 4 quarters.
Reyes Financial Architecture's Calidi Biotherapeutics position peaked at $152 in Q3 2025.
2 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2026.

Based on Reyes Financial Architecture's 13F filing for Q3 2026, filed 22 Oct 2026.